THE STATE OF MEDTECH & DIGITAL HEALTH INNOVATION: A NEW DECADE

Participate in a landmark study on the impact of MedTech and Digital Health regulation and reimbursement from 2010 to 2020

Today's MedTech leaders shaping tomorrow's regulatory landscape

Advance industry priorities for regulatory and reimbursement by participating in a study ten years in the making.

 

Conducted by a leading university, this IRB exempt study aims to interview executive thought-leaders across medtech and digital health to examine trends, establish benchmarks, and inform future decision-making on regulatory and reimbursement. 

 
 

MedTech & Digital Innovation study featured on DeviceTalks

Kwame Ulmer, study co-lead and former FDA deputy director and branch chief, sits down with Tom Salemi at DeviceTalks to share how this study aims to bring together the innovation ecosystem to be a part of breakthrough research to inform the advancement of regulatory and reimbursement. 

DTpod21_Herrera-Ulmer_1200x627_Vs1.jpg

What you need to do to participate in this study:

checkmark blue.png

Schedule a live 30 minute interview with our research team 

checkmark blue.png

Choose one novel medical device or digital health technology that achieved US regulatory approval between 2010 and 2020. 

checkmark blue.png

Consult with your CEO / CFO or regulatory / clinical officer on key regulatory activities and costs

checkmark blue.png

Participating companies will receive early access to the study report in Q3 2021

checkmark blue.png

First 50 participants will receive a $50 honoraria

What questions will be explored? 

hourglass.png

How long does it really take innovations to get to market?

Location.png

Do digital health and AI / ML have a clear path to market?

rocket.png

Is breakthrough designation breaking down regulatory barriers to access?

obstacle.png

Is reimbursement the new barrier to innovation?

earth.png

Is the U.S. keeping pace with Europe, Japan, and China?

Looking Ahead.png

What is next on the regulatory and reimbursement horizon?

 

What information is needed?

To participate in the study, please acquire information on:

required to achieve one of the following FDA pathways for a medtech product:

510(k)

PMA

De Novo

across the following milestones (where applicable):

R&D

idea.png

Clinical Development

Regulatory Clearance

Product

Launch

Clinical Studies

hospital.png
checklist.png
Regulatory.png

Reimbursement

money.png
rocket.png

For more information on what data is needed before starting your interview:

Stock Exchange
money_edited_edited_edited.png

Cost

The Time
clock_edited_edited_edited_edited_edited

Time

Doctor Using Digital Tablet
support_edited_edited.png

Resources

On the Phone
review_edited_edited.png

Experience

Which global regulatory markets will be examined?

USmap3d.jpg

U.S. FDA

EUmap 3D.jpg

European CE Mark

Japan Icon.jpg

Japan PMDA

ChinaMap3D.gif

China NMPA

Results will be benchmarked across the following: 

What happens after the study is completed?

Industry report will be presented at leading conferences in 2021
 

Jennifer McCaney, PhD

Co-Executive Director, UCLA Biodesign 

Assistant Professor at the UCLA Anderson School of Management and Geffen School of Medicine, former Director of Medtech Innovator. 

Kwame Ulmer, MBA

Lecturer, UCLA Anderson  

Venture Partner at Wavemaker Three-Sixty Health former medtech executive, former Deputy Director at the FDA, and founder of Medtech Color. 

Heashot CKJ White Background.png

Christian Johnson, MBA

Fellow, UCLA Biodesign

Co-Founder and Board Member of Seed Consulting Group, former strategist and marketer at Edwards Lifesciences and various Healthtech startups.

Who is leading the research?

Want to learn more? 

1001 Gayley Avenue, Suite 216
Los Angeles, CA 90095

About this study

This study is strictly an independent research study led by the University of California Los Angeles. The investigators have no conflicts of interest to disclose. Individual company data will not be released to any regulatory bodies or entities. Study results will be published in aggregate for the benefit of advancing innovation in medical technology and digital health. This research has been certified as exempt from IRB review per 45 CFR 46.104 category 2 (IRB#20-001604).